New Zealand has approved funding for cetuximab to aid advanced bowel cancer patients.

New Zealand has approved funding for cetuximab (Erbitux), a drug for advanced bowel cancer patients, following years of advocacy by Bowel Cancer NZ. The funding is expected to benefit around 380 patients in its first year, with some receiving it for the first time. While this is a significant advancement, further efforts are needed to extend funding for other treatments, including options for BRAF-mutated colorectal cancer and bevacizumab, which has been pending for 14 years.

November 01, 2024
7 Articles